AWARD
A -- Toward Maximizing the Scientific Value of the Biologic Specimens from the Women's Health Initiative II
- Notice Date
- 2/5/2009
- Notice Type
- Award Notice
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-WH-09-01
- Point of Contact
- Peggy D Mills,, Phone: (301) 435-0345
- E-Mail Address
-
pm39m@nih.gov
- Small Business Set-Aside
- N/A
- Award Number
- BAA-NHLBI-WH-09-01
- Award Date
- 1/15/2009
- Awardee
- See Below, See Below, ,, United States
- Award Amount
- See Below
- Line Number
- See Below
- Description
- Toward Maximizing the Scientific Value of the Biologic Specimens from the Women's Health Initiative II The NIH has supported collection of blood samples and clinical data from participants in the three clinical trials and the observational study of the Women's Health Initiative (WHI) since 1993. This well-characterized population provides a rare and valuable scientific resource maintained under contracts between NHLBI and the WHI centers. Promoting optimal use on a national scale of such a resource requires a large and concerted effort which may exceed the research capacities of individual study locations, and of WHI as a whole. The NHLBI and the researchers it supports have a responsibility to the public in general, and the scientific community in particular, to encourage the most rapid scientific progress possible using these resources. In order to take full advantage of such resources and to maximize their research value, it is important that samples and data collected with public funds be made available, with the least amount of restrictions, to the largest possible number of qualified investigators in a timely manner. The NHLBI and NIH programs were reviewed to determine whether existing projects will satisfy the requirement, and the proposed activity was discussed with key staff in NHLBI and other NIH Institutes to determine that this BAA does not replicate other efforts. The WHI resource is unique in its scope, focus on diseases of older women, ethic and racial diversity, and in particular in that it includes several large randomized controlled clinical trials which are capable of yielding information that cannot be obtained from observational studies. Care will be taken to ensure that the investigations under this BAA will not duplicate those already performed by the WHI investigators and their colleagues. The original WHI study population included 161,808 postmenopausal women in the United States, 68,132 (42%) of whom were randomized to one or more components of the clinical trial (CT), and 93,676 (58%) of whom were enrolled in the observational study (OS) between 1993 and 1998. Recruitment criteria included being 50-79 years of age, being post-menopausal, and planning to live in the area of a given Clinical Center (CC) for three years, with specific exclusionary criteria for the Dietary Modification (DM) and Hormone Therapy (HT) Trial components. Specific study goals were set for ethnic distribution (20% minority women in the CT) and age distribution (30% for 50-59 years of age; 45% for 60-69; 25% for 70-79). The original cohort was followed until March 31, 2005, after which subjects were invited to enroll in the WHI Extension Study from 2005 to 2010. As of August 2006 there were 115,273 women (77% of eligibles) enrolled in the Extension Study, during which ascertainment of outcomes (including activities of daily life) has continued together with limited exposure data on use of hormone therapy, calcium/vitamin D supplements, and 24-hour recall of food intake (in a subset). This acquisition will employ a Broad Agency Announcement (BAA) to seek proposals that will maximize the scientific yield from the biologic resource and associated participant exposure and outcome data in the Women's Health Initiative (WHI), by soliciting the best ideas for laboratory-based research studies to apply to the WHI biologic resource. This second solicitation follows on a first solicitation issued in January, 2006. WHI collected extensive information on multiple outcomes, including any disease leading to overnight hospitalization, cancers, self-report of a number of additional conditions, measures of cognition/dementia, sleep, and functional status, amongst others. For this second BAA solicitation, proposals utilizing the data on any of the phenotypes or groups of phenotypes will be considered. It is anticipated that the research programs funded by this BAA will include applications of genomics, proteomics, and other laboratory investigations to the existing frozen samples of DNA, serum, plasma, red blood cells, and urine. The BAA will not fund new data collection and will make use of existing biologic specimens. In general, the BAA seeks innovative technologies that enable comprehensive, yet efficient, investigation of sets of markers associated with disease outcomes or treatment effects, or of groups of mediators that might substantively explain the pathway of exposure or treatment effects on disease. For example, genomic studies might include whole-genome and haplotype approaches and studies of sets of functional genes with related effects on an outcome. Studies that combine information from genes and gene products in the form of blood proteins could help to elucidate pathways. Studies on serum or plasma might include multiplex assays of a panel of markers, for example adipokines or cytokines, which allow a large number of markers to be tested using a modest amount of sample. On the other hand, focused studies on a more limited number of candidate genes or candidate markers will be considered if there are reasonably strong data supporting large effects from these individual markers that need to be confirmed in a large dataset, and their validation has potential public health implications. Broad Agency Announcements (BAA) are used by agencies to fulfill their requirements for scientific study and experimentation directed towards advancing the state-of-the art or increasing knowledge or understanding rather than focusing on a specific solution. Proposals received under this BAA will be evaluated in accordance with evaluation criteria as specified in the solicitation, through a peer review process. Proposals will not be evaluated against a specific Government need, as in the case of a conventional request for proposals (RFP), as they are not submitted in accordance with a common work statement. The primary basis for selecting proposals submitted in response to this BAA shall be technical excellence, importance to agency programs, and funds availability. The technical evaluation of proposals will be conducted through a peer review process in accordance with established criteria. The evaluation criteria shall evaluate the Offeror's scientific and technical approach, adequacy of the technical approach, the Offeror's capabilities, and the qualifications, capabilities experience, and availability of proposed key personnel. NHLBI program and administrative staff will determine importance to agency programs and availability of funds. In addition, past performance of the Offeror and the extent of small disadvantaged business concerns in performance of the program will also be evaluated in accordance with FAR 15.304. The North American Industry Classification System (NAICS) Code is 541712, Size Standard - 500 employees. It is anticipated that 10 to 14 cost reimbursement type contracts will be awarded for 2-year periods beginning on or about December 15, 2008. The solicitation will be in the form of a Broad Agency Announcement, numbered BAA-NHLBI-WH-09-01 and will be available electronically on or about September 27, 2007 and may be accessed through the Internet at the following address: http://www.fedbizopps.gov. under the Department of Health and Human Services, National Institutes of Health, National Heart Lung and Blood postings. Proposals will be due on or about January 29, 2008. Offerors are responsible for downloading their own copy of the solicitation and for routinely checking the Internet site for any solicitation amendments that may be issued by the Government. This advertisement does not commit the Government to award a contract. HHSN268200900002C Ohio State University Research Fdn 160 Kenny Rd Columbus, OH 43210 $2,698,165 HHSN268200900003C Fred Hutchinson Cancer Research Center 1100 Fairview Ave North, J6-500 Seattle, WA 98109-1024 $1,073,907 HHSN268200900004C Fred Hutchinson Cancer Research Center 1100 Fairview Ave North, J6-500 Seattle, WA 98109-1024 $1,116,370 HHSN268200900005C Sanford Research/ USD 1100 E 21st St., Ste 700 Sioux Falls, SD 57105 $729,352 HHSN268200900006C University of Pittsburgh 139 University Place Pittsburgh, PA 15260 $1,774,318 HHSN268200900007C Fred Hutchinson Cancer Research Center 1100 Fairview Ave North, J6-500 Seattle, WA 98109-1024 $1,741,607 HHSN268200900008C Fred Hutchinson Cancer Research Center 1100 Fairview Ave North, J6-500 Seattle, WA 98109-1024 $1,012,049 HHSN268200900009C Fred Hutchinson Cancer Research Center 1100 Fairview Ave North, J6-500 Seattle, WA 98109-1024 $1,926,913 HHSN268200900010C Albert Einstein College 1300 Morris Park Ave Bronx, NY 10461 $645,184 HHSN268200900011C Brigham & Women's Hospital 900 Commonwealth Ave Boston, MA 02215 $1,400,833
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=b75a501196e54ca952f214dda78afd55&tab=core&_cview=1)
- Record
- SN01745188-W 20090207/090205220247-b75a501196e54ca952f214dda78afd55 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |